BR9814472A - Compostos imunomoduladores contendo gama-glutamil e beta-aspartil, e métodos com os mesmos - Google Patents

Compostos imunomoduladores contendo gama-glutamil e beta-aspartil, e métodos com os mesmos

Info

Publication number
BR9814472A
BR9814472A BR9814472-3A BR9814472A BR9814472A BR 9814472 A BR9814472 A BR 9814472A BR 9814472 A BR9814472 A BR 9814472A BR 9814472 A BR9814472 A BR 9814472A
Authority
BR
Brazil
Prior art keywords
glutamyl
beta
methods
same
compounds containing
Prior art date
Application number
BR9814472-3A
Other languages
English (en)
Inventor
Edward T Wei
Alexander A Kolobov
Andrey S Simbirtsev
Original Assignee
Edward T Wei
Alexander A Kolobov
Andrey S Simbirtsev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26653944&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9814472(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU97120940/04A external-priority patent/RU2142958C1/ru
Application filed by Edward T Wei, Alexander A Kolobov, Andrey S Simbirtsev filed Critical Edward T Wei
Publication of BR9814472A publication Critical patent/BR9814472A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSTOS IMUNOMODULADORES CONTENDO GAMA-GLUTAMIL E BETA-ASPARTIL, E MéTODOS COM OS MESMOS". Trata-se de compostos imunoestimulantes, mais particularmente compostos imunoestimulantes que incluem uma porção y-L-glutamil, y-D-glutamil, <225>-L-aspartil, ou <225>-D-aspartil que estimula a maturação e a diferenciação de determinadas classes das células brancas do sangue dentro do corpo, sendo que essa estimulação seletiva da diferenciação e da proliferação das células brancas do sangue intensifica as defesas do corpo contra os organismos causadores de doenças e também modula e melhora as condições auto-inflamatórias.
BR9814472-3A 1997-12-25 1998-12-22 Compostos imunomoduladores contendo gama-glutamil e beta-aspartil, e métodos com os mesmos BR9814472A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU97120940/04A RU2142958C1 (ru) 1997-12-25 1997-12-25 Пептид, обладающий иммуномодулирующей активностью, и препарат на его основе
US09/031,842 US5916878A (en) 1995-11-28 1998-02-27 γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
PCT/US1998/027291 WO1999033799A1 (en) 1997-12-25 1998-12-22 Gamma-glutamyl and beta-aspartyl containing immunomodulator compounds and methods therewith

Publications (1)

Publication Number Publication Date
BR9814472A true BR9814472A (pt) 2001-10-23

Family

ID=26653944

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814472-3A BR9814472A (pt) 1997-12-25 1998-12-22 Compostos imunomoduladores contendo gama-glutamil e beta-aspartil, e métodos com os mesmos

Country Status (14)

Country Link
US (1) US5916878A (pt)
EP (1) EP1042286B1 (pt)
JP (1) JP4536918B2 (pt)
KR (2) KR100602529B1 (pt)
CN (1) CN1155571C (pt)
AU (1) AU754876B2 (pt)
BR (1) BR9814472A (pt)
CA (1) CA2316310C (pt)
CY (1) CY1111236T1 (pt)
IL (1) IL136937A0 (pt)
MX (1) MXPA00006369A (pt)
NO (1) NO317256B1 (pt)
NZ (1) NZ505489A (pt)
WO (1) WO1999033799A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2089179C1 (ru) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
US6251857B1 (en) 1995-12-14 2001-06-26 Novelos Therapeutics, Inc. Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
RU2144374C1 (ru) 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US20070142267A1 (en) * 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
WO2000063238A1 (en) * 1999-04-15 2000-10-26 Thymon, L.L.C. Nonextractive method of assaying thymopoietin
AU2001272234B2 (en) * 2000-07-24 2006-06-01 The University Of Queensland Compounds and inhibitors of phospholipases
EP1309552A4 (en) * 2000-07-24 2005-07-20 Univ Queensland COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES
US7173013B2 (en) * 2001-06-08 2007-02-06 Sciclone Pharmaceuticals, Inc. Treatment of tuberculosis using immunomodulator compounds
RU2229892C2 (ru) * 2001-06-08 2004-06-10 Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" Способ лечения туберкулеза легких
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
CA2566062A1 (en) * 2004-05-14 2005-12-01 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with immunomodulator compounds
US8193152B2 (en) * 2004-10-27 2012-06-05 The Board Of Regents Of The University Of Texas System Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds
WO2006116053A1 (en) * 2005-04-22 2006-11-02 Sciclone Pharmaceuticals, Inc. Immunomodulator compounds as vaccine enhancers
CA2649575A1 (en) * 2006-04-20 2007-11-01 Sciclone Pharmaceuticals, Inc. Treatment of melanoma
RU2301074C1 (ru) * 2006-05-30 2007-06-20 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Пептид, обладающий иммуногеропротекторным действием, фармацевтическая композиция на его основе и способ ее применения
CA2569204A1 (en) 2006-11-28 2008-05-28 Apotex Technologies Inc. Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium salt of d-isoglutamyl-d-tryptophan
CA2571645A1 (en) 2006-12-19 2008-06-19 Apotex Technologies Inc. Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture
MX2009008641A (es) * 2007-02-13 2009-09-14 Sciclone Pharmaceuticals Inc Composiciones para el tratamiento o prevencion del deterioro, lesion o daño a tejido debido a enfermedad de las mucosas.
CA2579119C (en) * 2007-02-16 2013-03-05 Apotex Technologies Inc. Crystalline forms of the mono-sodium salt of d-isoglutamyl-d-tryptophan
RU2007118237A (ru) * 2007-05-17 2008-11-27 ООО "Научно-производственна фирма Верта" (RU) Способ лечения аллергических заболеваний
JP2010536854A (ja) * 2007-08-23 2010-12-02 サイクローン・ファーマシューティカルズ・インコーポレイテッド 肺ガンの治療
CN104198718B (zh) * 2008-12-24 2017-11-10 学校法人庆应义塾 肝病标记物、其测定方法、装置和医药品的检验方法
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
WO2012040656A2 (en) * 2010-09-24 2012-03-29 Sciclone Pharmaceuticals, Inc. Biomarkers to track response to scv-07
CN102417474B (zh) * 2011-09-26 2014-07-02 深圳翰宇药业股份有限公司 D-异谷氨酰基-d-色氨酸制备的新方法
WO2013155595A1 (en) * 2012-04-18 2013-10-24 Apotex Technologies Inc. Process for the preparation of a monosodium salt of h-d-glu-(l-trp-oh)-oh and a crystalline form thereof
WO2013155592A1 (en) * 2012-04-18 2013-10-24 Apotex Technologies Inc. Crystal forms of golotimod and process for its manufacturing
RU2635968C1 (ru) * 2016-11-17 2017-11-17 Аллан Герович Бениашвили Способ лечения и профилактики состояний аллергического спектра

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125626A (en) * 1977-01-17 1978-11-14 Mt. Sinai School Of Medicine Of The City University Of New York Synthesis and use of L-γ-glutamyl-DOPA
US4568489A (en) * 1984-06-29 1986-02-04 E. R. Squibb & Sons, Inc. N-Acyl-γ-glutamyl imino and amino acids and esters
US4758551A (en) * 1986-07-08 1988-07-19 Cornell Research Foundation, Inc. Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types
US5206220A (en) * 1990-04-23 1993-04-27 Research Corporation Technologies, Inc. Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition
WO1992017191A1 (en) * 1991-04-01 1992-10-15 Cytoven Pharmaceutical dipeptide compositions and methods of use thereof
GB9113219D0 (en) * 1991-06-19 1991-08-07 Fujisawa Pharmaceutical Co Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
DE69230500D1 (de) * 1991-10-28 2000-02-03 Cytran Ltd Pharmazeutische Dipeptid Zusammensetzungen und Verwendungsmethoden.
AU6359594A (en) * 1993-03-04 1994-09-26 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
RU2107692C1 (ru) * 1995-06-07 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
WO1997019691A1 (en) * 1995-11-28 1997-06-05 Wei, Edward, T. Gamma-l-glutamyl containing immunomodulator compounds and methods therewith

Also Published As

Publication number Publication date
KR20060057027A (ko) 2006-05-25
CA2316310A1 (en) 1999-07-08
US5916878A (en) 1999-06-29
NO20003312D0 (no) 2000-06-23
KR100602529B1 (ko) 2006-07-19
CY1111236T1 (el) 2015-06-11
AU754876B2 (en) 2002-11-28
CA2316310C (en) 2008-02-19
IL136937A0 (en) 2001-06-14
NO317256B1 (no) 2004-09-27
KR100623104B1 (ko) 2006-09-15
EP1042286B1 (en) 2010-08-25
JP2001527065A (ja) 2001-12-25
NZ505489A (en) 2003-02-28
CN1155571C (zh) 2004-06-30
AU2090999A (en) 1999-07-19
EP1042286A1 (en) 2000-10-11
WO1999033799A1 (en) 1999-07-08
NO20003312L (no) 2000-08-21
JP4536918B2 (ja) 2010-09-01
CN1284943A (zh) 2001-02-21
KR20010033617A (ko) 2001-04-25
MXPA00006369A (es) 2002-08-06

Similar Documents

Publication Publication Date Title
BR9814472A (pt) Compostos imunomoduladores contendo gama-glutamil e beta-aspartil, e métodos com os mesmos
CA2259163A1 (en) Nt-3 and bdnf analogs having improved circulating life and/or absorption
NO984603L (no) Feste-element samt ligament festet til dette
DE69419839D1 (de) Mittel zur Stabilizierung von entproteinisiertem Naturkautschuklatex
PT79182B (de) Mittel zur transdermalen applikation von arzneimittelwirkstoffen
ATE197549T1 (de) Methoden zur regulation der den magen und darm betreffenden motilitaet
CA1268123C (en) DIETARY PRODUCTS CONTAINING METHYLSULFONYLMETHANE AND THEIR USE
DE69623855D1 (de) Implantierbare medizinische Vorrichtung
CA2274596A1 (en) Compositions and methods for enhancing intestinal function
EP0787476A3 (en) Device for activating cells of a human body
BR9403783A (pt) Uso de uma composição cosmética
ES2049318T3 (es) Implante oseo.
AU1798995A (en) Use of extracts of filamentous bacteria as cosmetic agents to combat ageing of the skin
BG102696A (en) Antipsoriasic nail varnish
DE69400332D1 (de) Gel-ähnliche Zusammensetzung enthaltend Organopolysiloxane, ohne Geliermittel zur Kosmetische und Dermatologische Anwendung
NO870772D0 (no) Vevplasminogenaktivator for normale humane tykktarmceller.
ATE275387T1 (de) Kosmetische mittel enthaltende pflanzenextrakten
DE68913739D1 (de) Kosmetische und hautbehandlungs-zusammensetzungen.
ATE239474T1 (de) Verwendung von levobupivacain
DE69623390D1 (de) Aktive implantierbare medizinische Vorrichtung, insbesondere Herzschrittmacher oder Defibrillator
ATE187081T1 (de) Sammelvorrichtung
KR970064396A (ko) 스트레스 완화용 사료
DE3767731D1 (de) Prostacyclinanalog, dieses als aktives bestandteil enthaltendes, den blutumlauf verbesserndes mittel und gegen magengeschwuere wirkendes mittel.
NO170661C (no) Anordning for behandling av yngel paa tidlige utviklingsstadier
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: CRAGMONT PHARMACEUTICALS, LLC (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NOS ARTIGOS 8O, 10 ( VIII ), 13 E 25 DA LPI 9279/96

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time